Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-31 10:09 am Sale |
2024-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
The Vanguard Group | 8,200,903 4.800% |
-239,827 (-2.84%) |
Filing History |
| 2024-11-12 5:59 pm Unchanged |
2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
The Vanguard Group | 8,440,730 5.000% |
0 (Unchanged) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BLACKROCK INC BLK |
11,210,671 6.700% |
0 (Unchanged) |
Filing History |
| 2024-11-04 2:15 pm Purchase |
2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
The Vanguard Group | 8,440,730 5.000% |
8,440,730 (New Position) |
Filing History |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BLACKROCK INC BLK |
11,210,671 6.700% |
3,049,924 (+37.37%) |
Filing History |
| 2024-02-14 7:36 pm Purchase |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 11,494,437 6.700% |
1,165,788 (+11.29%) |
Filing History |
| 2024-02-14 4:44 pm Purchase |
2022-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ACORN BIOVENTURES, L.P. | 17,755,869 9.990% |
17,755,869 (New Position) |
Filing History |
| 2024-02-14 4:32 pm Sale |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Lincoln Park Capital Fund LLC | 1,600,136 0.947% |
-209,951 (-11.60%) |
Filing History |
| 2024-02-13 6:55 pm Purchase |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BCLS I Investco, LP | 16,915,784 11.000% |
4,713,274 (+38.63%) |
Filing History |
| 2024-02-07 5:09 pm Sale |
2024-01-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BLACKROCK INC BLK |
8,160,747 4.900% |
-256,777 (-3.05%) |
Filing History |
| 2024-01-31 2:08 pm Purchase |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BLACKROCK INC BLK |
8,417,524 5.000% |
7,343,033 (+683.40%) |
Filing History |
| 2024-01-16 4:18 pm Sale |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
MILLENNIUM MANAGEMENT LLC | 1,664,317 1.000% |
-6,604,499 (-79.87%) |
Filing History |
| 2024-01-08 10:26 am Sale |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Empery Asset Management, LP | 4,549,605 2.650% |
-1,649,079 (-26.60%) |
Filing History |
| 2023-06-16 4:04 pm Purchase |
2023-06-09 | 13G | X4 Pharmaceuticals, Inc. XFOR |
MILLENNIUM MANAGEMENT LLC | 8,268,816 5.200% |
8,268,816 (New Position) |
Filing History |
| 2023-05-26 3:03 pm Purchase |
2023-05-18 | 13D | X4 Pharmaceuticals, Inc. XFOR |
Growth Equity Opportunities 18 VGE LLC | 15,742,792 9.990% |
3,605,999 (+29.71%) |
Filing History |
| 2023-02-14 5:24 pm Purchase |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 10,328,649 8.200% |
8,492,300 (+462.46%) |
Filing History |
| 2023-02-14 4:18 pm Sale |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Point72 Asset Management, L.P. | 913,242 1.300% |
-719,962 (-44.08%) |
Filing History |
| 2023-02-14 11:26 am Sale |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Ikarian Capital LLC | 349,133 0.300% |
-1,915,358 (-84.58%) |
Filing History |
| 2023-02-14 06:34 am Purchase |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BCLS I Investco, LP | 12,202,510 11.000% |
9,315,968 (+322.74%) |
Filing History |
| 2023-02-13 5:51 pm Sale |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
BIOTECHNOLOGY VALUE FUND L P | 2,258,400 1.900% |
-769,272 (-25.41%) |
Filing History |